Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Faron Pharmaceuticals

0.40 EUR+0.63 %8/9 17:29
5,784 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
+0.63 %
-15.68 %
-21.16 %
-32.67 %
-79.93 %
-81.73 %
-89.21 %
-91.45 %
-88.01 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
91.27M EUR
Turnover
499.31K EUR
P/E (adj.) (26e)
-4.46
EV/EBIT (adj.) (26e)
-3.6
P/B (26e)
20.87
EV/S (26e)
20,332.1
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
2026-08-26
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-08-27

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Blaze, status updated. All (2) sites are recruiting. clinicaltrials.gov ClinicalTrials.gov
3 hours ago
by Koodinikkari
12
HCM has been steadily selling a fairly small amount, with the monthly change being only about 2 million shares, so a large part of last week’s selling was Pentwater’s. Today, for the first time, there was a larger batch in the closing auction, so could it be possible that those 626...
23 hours ago
by StockTycoon
10
According to the schedule, it should be ready around January 2030, so there’s still a long wait ahead
3 hours ago
by Sebastian Soderholm
7
Today it was HCM’s turn to flag their sales: MFN – 7 Sep 26 Faron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COM... Faron Pharmaceuticals Ltd | Company announcement | September 07, 2026 at 18:30:00 EEST TR-1: Standard form for notification of major holdings +------...
yesterday
6
If Juho would just talk to partner or buyer candidates now, and no longer to investors… well, I still don’t interpret that in any way. I mean that event posted above on September 14th-16th.
9/5/2026, 4:27 PM
by TurskanHaalija
6
Faron Pipeline - Faron Faron’s focus is on the development of bexmarilimab, a first-in-class, humanized monoclonal antibody that binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, and a novel immune checkpoint... Est. reading...
yesterday
by Koodinikkari
5
Soft tissue sarcoma Bex+Doxorubicin study is being conducted by Medsir in Spain. Medsir collaborates with many parties, so it is probably possible that they also collaborate with Tampere in some matters.
yesterday
by Koodinikkari
4
Read more on our forum
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release2026-09-07 17:30

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-09-04 12:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Press release2026-08-28 10:35

Redeye: Faron Pharmaceuticals (H1 Review): Setting up for an eventful period of clinical development

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-08-28 08:34

DNB Carnegie Access: Faron Pharmaceuticals: BEXERA trial on track to start in Q4 – H1 review

Faron Pharmaceuticals
Faron H1'26: New trials set to get underway
Research2026-08-27 10:20 by
Antti Siltanen

Faron H1'26: New trials set to get underway

Several new trials will begin in the coming months.

Faron Pharmaceuticals
Press release2026-08-27 08:00

Faron Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial

Faron Pharmaceuticals
Faron Pharmaceuticals, H1'26
Webcast2026-08-26 14:00

Faron Pharmaceuticals, H1'26

Faron Pharmaceuticals
Regulatory press release2026-08-26 08:00

Faron Pharmaceuticals Ltd: Half-year financial results 1 January – 30 June 2026

Faron Pharmaceuticals
Faron H1'26 preview: BEXERA trial is being initiated
Analyst Comment2026-08-25 09:37 by
Antti Siltanen

Faron H1'26 preview: BEXERA trial is being initiated

The company's key value driver, the BEXERA trial, will start in H2.

Faron Pharmaceuticals
Regulatory press release2026-08-19 08:00

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Faron Pharmaceuticals
Regulatory press release2026-08-05 13:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-08-04 15:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-08-03 14:00

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Faron Pharmaceuticals
Faron reports first OS results from frontline MDS patients
Analyst Comment2026-07-28 08:33 by
Antti Siltanen

Faron reports first OS results from frontline MDS patients

Median overall survival has not been reached in 2/3 of patient groups after 14.9 months of follow-up.

Faron Pharmaceuticals
Regulatory press release2026-07-27 08:00

Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial

Faron Pharmaceuticals
Regulatory press release2026-07-24 08:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Faron updated the status of investigator-initiated bexmarilimab studies
Analyst Comment2026-07-14 08:16 by
Atte Riikola

Faron updated the status of investigator-initiated bexmarilimab studies

The bexmarilimab cohort in the FINPROVE trial was discontinued, but the company's own blood cancer trials are moving forward.

Faron Pharmaceuticals
Press release2026-07-13 08:00

Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab

Faron Pharmaceuticals
Regulatory press release2026-07-01 12:00

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals
Regulatory press release2026-06-22 15:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals